CYCLODEXTRINS AND THEIR APPLICATION IN ENHANCING THE SOLUBILITY, DISSOLUTION RATE AND BIOAVAILABILITY
Abstract
Objective: The main objective is to describe the applications of cyclodextrins in enhancing the solubility, dissolution rate and bioavailability.Methods and Sources: Low aqueous solubility is the major problem encountered with formulation development of drug product. Drug with poor water solubility cause slow dissolution rates, generally show erratic and incomplete absorption leading to low bioavailability when administered orally. In the present paper the applications of the cyclodextrin are discussed. In the pharmaceutical industry cyclodextrins have mainly been used as complexing agents to increase aqueous solubility of poorly soluble drugs, and to increase their bioavailability and stability. Â Conclusion: Bioavailability of poorly water soluble drugs can be enhanced by using cyclodextrins.Keywords: Biopharmaceutical classification system, solubility, absorption, bioavailabilityReferences
Egan WJ, Merz KM, et al. Prediction of drug absorption using multivariate statistics. Journal of Medicinal Chemistry, 2000; 43 (21): 3867-3877.
Custodio JM, Wu CY, et al. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Advanced Drug Delivery Reviews, 2008, 60, 6, 717-733.
Smith DA. Design of drugs through a consideration of drug metabolism and pharmacokinetics. European Journal of Drug Metabolism and Pharmacokinetics. 1994; 3: 193-199.
Savjani KT, Gajjar AK, et al. Drug solubility: Importance and enhancement techniques. ISRN Pharmaceutics, 2012; 1-10.
Villiers A, Hebd CR. Sur la fermentation de la fecule par I’ action du ferment butyrique. Seances Academia Sciences, 1891; 112: 536-538.
Szejtli J. Cyclodextrin technology, Kluwer Academic Publisher, Dordrecht. 1988.
Duchêne D. New trends in cyclodextrins and derivatives, Editions de Santé, Paris, (Ed.), 1991.
Rajewski RA, Stella VJ. Pharmaceutical applications of cyclodextrins. 2. in vivo drug delivery. Journal of Pharmaceutical Sciences, 1996; 85(11): 1142-1169.
Irie T. Uekama K. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. Journal of Pharmaceutical Sciences, 1997; 86(2):147-162.
Stella VJ, Rajewski RA. Cyclodextrins: Their future in drug formulation and delivery. Pharmaceutical Research, 1997; 14(5): 556-567.
Uekama K. Cyclodextrins in drug delivery system. Advanced Drug Delivery Reviews, 1999; 36(1): 1-142.
D’souza, VT, Lipkowitz KB. Cyclodextrins: Introduction. Chemical Reviews, 1998; 98(5): 1741-1742.
Thompson DO. Cyclodextrins- enabling excipients: Their present and future use in pharmaceuticals. Critical Reviewsâ„¢ in Therapeutic Drug Carrier Systems, 1997; 14(1): 1-104.
Zhang MQ, Rees DC. A review of recent applications of cyclodextrins for drug discovery. Expert Opinion on Therapeutic Patents, 1999; 12: 1697-1717.
Del Valle EMM. Cyclodextrins and their uses: A review. Process Biochemistry, 2004; 39(9): 1033-1046.
Bekers O, Uijtendaal EV, et al. Cyclodextrins in the pharmaceutical field. Drug Development and Industrial Pharmacy, 1991; 17(11): 1503-1549.
Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. Journal of Pharmaceutical Sciences, 1996; 85(10): 1017-1025.
Frömming KH, Szejtli J, et al. Cyclodextrins in pharmacy. Kluwer Academic Publishers, Dordrecht, 1994.
French D. The schardinger dextrins. Advances in carbohydrate chemistry, 1957; 12: 189-260.
Miyazawa I, Ueda H, et al. Physicochemical properties and inclusion complex formation of δ-cyclodextrin. European Journal of Pharmaceutical Sciences, 1995; 3(3): 153-162.
Nash RA. In: Hand book of pharmaceutical excipients. American Pharmaceutical Association and Pharmacy, Press: London, 145, 1994.
Saenger W. Cyclodextrin inclusion compounds in research and industry. Chemie International Edition in English, 1980; 19(5): 344-362.
Zhou X, Kaplan ML. Soluble amylose cornstarch is more digestible than soluble amylopectin potato starch in rats. The Journal of Nutrition, 1997; 127(7): 1349-5136.
Hedges A. Cyclodextrins: properties and applications. In: BeMiller J, Whistler R (Eds.), Starch Chemistry and Technology, 3rd ed., New York, Academic Press, 2009, 833-852.
Loftsson T, Brewster ME, et al. Role of cyclodextrins in improving oral drug delivery. American Journal of Drug Delivery, 2004; 2(4): 261-275.
Szejtli J. Cyclodextrins and their inclusion complexes, Akademiai, Kiado, Budapest, Hungary, pp.13, 1982.
Gandhi RB, Karara AH. Characterization, dissolution and diffusion properties of tolbutamide-β-cyclodextrin complex system. Drug Development and Industrial Pharmacy, 1988; 14(5): 657-682.
Fromming KH, Szejtii J, et al. Cyclodextrins in pharmacy, Kluwer Acad. Publ., Dordrecht, 1994.
Manoj M, Nitalikar, et al. The cyclodextrins: a review, Journal of Current Pharmaceutical Research, 2012; 10(1): 01-06.
Fernandes CM, Veiga FJB. Effect of the hydrophobic nature of triacetyl-b-cyclodextrin on the complexation with nicardipine hydrochloride: Physicochemical and dissolution properties of the kneaded and spray-dried complexes. Chemical and Pharmaceutical Bulletin, 2002; 50(12):1597-1602.
Cirri M, Rangoni C, et al. Development of fast-dissolving tablets of flurbiprofen-cyclodextrin complexes. Drug Development and Industrial Pharmacy, 2005; 31: 697-707.
Cunha-Filho MSS, Dacunha-Marinho B, et al. Characterization of β-lapachone and methylated β cyclodextrin solid-state systems. AAPS PharmSciTech, 2007; 8: 1-10.
Parikh RK, Mansuri NS, et al. Dissolution enhancement of nimesulide using complexation and salt formation techniques. Indian Drugs, 2005; 42: 149-53.
Moyano JR, Blanco MJA, et al. Solid-state characterization and dissolution characteristics of gliclazide-β-cyclodextrin inclusion complexes. International Journal of Pharmaceutics, 1997; 148(2): 211-217.
Doijad RC, Kanakal MM, et al. Studies on piroxicam-beta-cyclodextrin inclusion complexes. Indian Pharmacists.VI, 2007; 6: 94-98.
Vozone CM, Marques HMC. Complexation of budesonide in cyclodextrins and particle aerodynamic characterization of the complex solid form for dry powder inhalation. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2002; 44(1-4): 111-116.
Pandya SJ, Mansuri JS, et al. Compatible Polymer used as complexes in various drug delivery systems: β-Cyclodextrin. Pharmainfo.net, 2008; 6(2): 33-38.
Chaudhary A, Nagaich U, et al. Enhancement of solubilization and bioavailability of poorly soluble drugs by physical and chemical modifications: A recent review. Journal of Advanced Pharmacy Education & Research, 2012; 2(1): 32-67.
Palakodaty S, York P. Phase behavioral effects on particle formation processes using supercritical fluids. Pharmaceutical Research, 2004; 141: 219-226.
Tirucherai GS, Mitra AK. Effect of hydroxypropyl beta cyclodextrin complexation on aqueous solubility, stability, and corneal permeation of acyl ester prodrugs of ganciclovier. AAPS PharmSciTech, 2003; 4(3): 124-135.
Van HT, Piel G, et al. Application of supercritical carbon dioxide for the preparation of a piroxicam-β-Cyclodextrin Inclusion Compound. Pharmaceutical research, 1999; 16(12): 1864-1870.
Al-Marzouqui AH, Jobe B, et al. Evaluation of supercritical fluid technology as preparative technique of benzocaine cyclodextrin complexes-Comparison with conventional methods. Journal of Pharmaceutical and Biomedical Analysis, 2007; 43: 566-574.
Vamsi KM, Gowrisankar D. Role of Supercritical fluids in the Pharmaceutical Research-A Review. Indian Journal of Pharmacy Education and Research, 2007; 41(1): 10-17.
Cramer F, Saenger W, et al. Inclusion Compounds. XIX.1a The formation of inclusion compounds of α-cyclodextrin in aqueous solutions. Thermodynamics and Kinetics. Journal of the American Chemical Society, 1967; 89(1): 14-20.
Miller LA, Carrier RL, et al. Practical considerations in development of solid dosage forms that contain cyclodextrin. Journal of Pharmaceutical Sciences, 2007; 96(7): 1691-1707.
Challa R, Ahuja A, et al. Cyclodextrins in drug delivery: an updated review. AAPS PharmSciTech, 2005; 6(2): E329– E357.
Waleczek KJ, Marques HM, et al. Phase solubility studies of pure (-)-alpha-bisabolol and camomile essential oil with beta-cyclodextrin. European Journal of Pharmaceutics and Biopharmaceutics, 2003; 55: 247-251.
Higuchi T, Connors KA. Phase-solubility techniques, In: advances in analytical chemistry and instrumentation, Reilly, C.N., Ed., Wiley-Interscience. New York, 1965; 4, 117.
Osadebe PO, Onugwu LE, et al. Energetics of the interaction between piroxicam and beta-cyclodextrin (β-CD) in inclusion complexes, Scientific Research and Essays, 2008; 3(3): 086-093.
Hedges AR. Industrial applications of cyclodextrins. Chemical Reviews, 1998; 98(5): 2035-2044.
Brewster ME, Loftsson T. Cyclodextrins as pharmaceutical solubilizers. Advanced Drug Delivery Reviews, 2007; 59 (7): 645-666.
Bratu I, Hernanz A, et al. FT-IR spectroscopy of inclusion complexes of b-cyclodextrin with fenbufen and ibuprofen. Romanian Journal of Physics, 2005; 50: 1063-1069.
Uekama K, Hirayama F, et al. Cyclodextrin drug carrier systems. Chemical Reviews, 1998; 98(5): 2045-2076.
Smola M, Vandamme T. Taste masking of unpleasant oral drugs. In: Mashkevich BO (Ed.), Drug Delivery Research Advances. New York, Nova Science Publishers, 2007:117-152.
Forgács E, Cserháti T. Study of the interaction of some steroidal drugs with cyclodextrin derivatives. Analytical Letters, 2004; 37(9): 1897-1908.
Steed JW, Turner DR, Wallace KJ. Core concepts in supramolecular chemistry. West Sussex, England, John Wiley & Sons Ltd., 2007, pp. 94.
Bodor N, Drustrup J, et al. Effect of cyclodextrins on the solubility and stability of a novel soft corticosteroid, loteprednol etabonate. Pharmazie. 2000; 55(3): 206-209.
Veiga MD, Ahsan F, et al. Influence of surfactants (present in the dissolution media) on the release behaviour of tolbutamide from its inclusion complex with β-cyclodextrin. European Journal of Pharmaceutical Sciences, 2000; 9(3): 291-299.
Arias MJ, Moyano JR, et al. Study of omeprazole-γ-cyclodextrin complexation in the solid state. Drug Development and Industrial Pharmacy, 2000; 26(3): 253-259.
Koester LS, Guterres SS, et al. Ofloxacin/β-cyclodextrin complexation. Drug Development and Industrial Pharmacy, 2001; 27(6): 533-540.
Doliwa A, Santoyo S, et al. Influence of piroxicam: Hydroxypropyl- β cyclodextrin complexation on the in vitro permeation and skin retention of piroxicam. Skin Pharmacology. Physiology, 2001; 14: 97-107.
Pose-Vilamovo B, Lopez P, et al. Improvement of water solubility of sulfamethizole through its complexation with β- and hydroxypropyl-β-cyclodextrin: Characterization of the interaction in solution and in solid state. European Journal of Pharmaceutical Sciences, 2001; 13(3): 325- 331.
Nijhawan R, Agarwal SP. Development of an ophthalmic formulation containing ciprofloxacin-hydroxypropyl-b-cyclodextrin complex. Bollettino chimico farmaceutico, 2003; 142(5): 214-219.
Archontaki HA, Vertzoni MV, et al. Study on the inclusion complexes of bromazepam with β- and β-hydroxypropyl-cyclodextrins. Journal of Pharmaceutical and Biomedical Analysis, 2002; 28(3-4): 761-769.
Spamer E, Muller DG, et al. Characterization of the complexes of furosemide with 2-hydroxypropyl-β-cyclodextrin and sulfobutyl ether-7-β-cyclodextrin. European Journal of Pharmaceutical Sciences, 2002; 16(4-5): 247-253.
Bayomi MA, Abanumay KA, et al. Effect of inclusion complexation with cyclodextrins on photostability of nifedipine in solid state. International Journal of Pharmacy, 2002; 243(1-2): 107-117.
Femandes CM, Veiga FJ. Effect of the Hydrophobic Nature of Triacetyl-β-cyclodextrin on the complexation with nicardipine hydrochloride: Physicochemical and dissolution properties of the kneaded and spray-dried complexes. Chemical and Pharmaceutical Bulletin, 2002; 50 (12): 1597-1602.
Koontz JL, Marcy JE. Formation of natamycin: Cyclodextrin inclusion complexes and their characterization. Journal of Agriculture and Food Chemistry, 2003; 51(24): 7106-7110.
Kopecky F, Kopecka B, et al. Dissolution of nimodipine in an aqueous solution of hydroxyethyl-beta-cyclodextrin and a review of solubility of nimodipine with cyclodextrins. Ceskaslov Farmacie, 2003; 52(1): 33-38.
Nasongkia N, Wiedmann AF, et al. Enhancement of solubility and bioavailability of β-lapachone using cyclodextrin inclusion complexes. Pharmaceutical Research, 2003; 20(10): 1626-1633.
Wong JW, Yuen KH, et al. Inclusion complexation of artemisinin with α-, β-, and γ-cyclodextrins. Drug Development and Industrial Pharmacy, 2003; 29(9): 1035-1044.
Liu X, Lin HS, et al. Inclusion of acitretin into cyclodextrins: Phase solubility, photostability, and physicochemical characterization. Journal of Pharmaceutical Sciences, 2003; 92(12): 2449-2457.
Koester LS, Xavier CR, et al. Influence of β-cyclodextrin complexation on carbamazepine release from hydroxypropyl methylcellulose matrix tablets. European Journal of Pharmaceutics and BioPharmaceutics, 2003; 55(1): 85-91.
Mord PC, Cim M, et al. Enhancement of dehydro epiandrosterone solubility and bioavailability by ternary complexation with α-cyclodextrin and glycine. Journal of Pharmaceutical Sciences, 2004; 93(5): 1374-1374.
Holvoet C, Heyden, YV, et al. Inclusion complexation of lorazepam with different cyclodextrins suitable for parenteral use. Drug Development and Industrial Pharmacy, 2005; 31(6): 567-575.
Zhang A, Wen Y. Characterization of inclusion complexation between fenoxaprop-p-ethyl and cyclodextrin. Journal of Agriculture and Food Chemistry, 2005; 53(18): 7193-7197.
Holvoet C, Heyden YV, et al. Inclusion complexation of diazepam with different cyclodextrins in formulations for parenteral use. Pharmazie, 2005; 60(8): 598-603.
Jug M, Be A, et al. Development of a cyclodextrin-based nasal delivery system for lorazepam. Drug Development and Industrial Pharmacy, 2008; 34(8): 817-826.
Shinde VR, Shelake MR, et al. Enhanced solubility and dissolution rate of lamotrigine by inclusion complexation and solid dispersion technique. Journal of Pharmacy and Pharmacology, 2008; 60(9): 1121-1129.
Cruz JR, Becker BA, et al. NMR characterization of the host–guest inclusion complex between βâ€cyclodextrin and doxepin. Magnetic Resonance in Chemistry, 2008; 46(9): 838-845.
Sarle A, Szente L, et al. Enhancement of drug solubility in supramolecular and colloidal systems. Journal of Pharmaceutical Sciences, 2009; 98(2): 484-494.
Hirlekar RS, Sonawane SN, et al. Studies on the effect of water-soluble polymers on drug-cyclodextrin complex solubility. AAPS Pharm Sci Tech., 2009; 10(3): 858-863.
Pokharkar V, Khanna A, et al. Ternary complexation of carvedilol, β-cyclodextrin and citric acid for mouth-dissolving tablet formulation. Acta Pharmaceutica, 2009; 59(2): 121-132.
Chowdary KPR, Sundari PT, et al. Formulation and evaluation of piroxicam and aceclofenac tablets employing Prosolve by direct compression method. Asian Journal of Chemistry, 2009; 21(8): 5847-5850.
Jansook P, Kurkov SV, et al. Cyclodextrins as solubilizers: Formation of complex aggregates. Journal of Pharmaceutical Sciences. 2010; 99(2): 719-729.
Madan J, Dhiman N, et al. Inclusion complexes of noscapine in β-cyclodextrin offer better solubility and improved pharmacokinetics. Cancer Chemotheraphy and Pharmacology, 2010; 65(3): 537-548.
Jug M, Maestrelli F, et al. Preparation and solid-state characterization of bupivacaine hydrochloride cyclodextrin complexes aimed for buccal delivery. Journal of Pharmaceutical and Biomedical Analysis, 2010; 52(1): 9-18.
Patel VP, Gohel MC, et al. In vitro dissolution enhancement of felodipine. Indo-Global Journal of Pharmaceutical Sciences, 2011; 1(2): 194-205.
Mura P, Faucci MT, et al. Characterization of physicochemical properties of naproxen systems with amorphous β-cyclodextrin-epichlorohydrin polymers. Journal of Pharmaceutical and Biomedical Analysis, 2002; 29(6): 1015-1024.
Zingone G, Rubessa F. Preformulation study of the inclusion complex warfarin-β-cyclodextrin. International Journal of Pharmaceutics, 2005; 291(1-2); 3-10.
Chowdary KPR, Prakasarao KS. A Factorial Study on the effects of β- cyclodextrin and Poloxamer 407 on the dissolution rate of valsartan from CD complexes and their tablets. Research Journal of Pharmaceutical Biological and Chemical Sciences, 2011; 2(3): 438- 444.
Chowdary KPR, Prakasarao KS, et al. A factorial study on the effects of hydroxypropyl β cyclodextrin and poloxamer on the solubility and dissolution rate of nimesulide. International Journal of Pharmaceuticals Sciences and Research, 2012; 3(2): 460-464
Chowdary KPR, Prakasarao KS, et al. Formulation and evaluation of etoricoxib tablets employing cyclodextrin- Poloxamer 407 – PVP K30 inclusion complexes. International Journal of Applied Biology and Pharmaceutical Technology, 2011; 2(4): 43-48.
Mihajlovic T, Kachrimanis K, et al. Improvement of aripiprazole solubility by complexation with (2-Hydroxy)propyl-β-cyclodextrin using spray drying technique. AAPSPharmSciTech, 2012; 13(2): 623-31.
Patil PH, Belgamwar VS, et al. Solubility enhancement of raloxifene using inclusion complexes and cogrinding method. Journal of Pharmaceutics, 2013; 9: 1-9.
Shankar KR, Chowdary KPR. A factorial study on enhancement of solubility and dissolution rate of efavirenz employing β-cyclodentrin, soluplus and PVPK30. World Journal of Pharmaceutical Research, 2013; 2(3): 578-586.
Inoue Y, Sekiya N, et al. Stabilizing effect of β-cyclodextrin on limaprost, a PGE1 derivative, in limaprost alfadex Tablets (Opalmon®) in highly humid conditions. Chemical and Pharmaceutical Bulletin. 2014; 62(8): 786-792.
Chowdary KPR, Prakasarao KS. Formulation development of pioglitazone tablets employing β cyclodextrin poloxamer 407- PVP K30: A factorial study. Der Pharmacia Lettre, 2011; 3(6): 24-30.
Kovvasu SPR, Chowdary KPR. Formulation development and in vivo evaluation of pioglitazone inclusion complexes: A factorial study. International Journal of Applied Pharmaceutics, 2018; 10(3): 49-55.
Thapa P, Thapa R, et al. Solubility enhancement of domperidone fast disintegrating tablet using hydroxypropyl-β-cyclodextrin by inclusion complexation technique. Pharmacology & Pharmacy, 2014; 5: 238-249.
Dey S, Chattopadhyay S, et al. Formulation and evaluation of fixed-dose combination of bilayer gastroretentive matrix tablet containing atorvastatin as fast-release and atenolol as sustained-release. BioMed Research International, Article ID 396106, 2014; 1- 12.
Shankar KR, Chowdary KPR. A factorial study of formulation of ritonavir tablets employing β cyclodextrin, soluplus and PVP K30. World Journal of Pharmaceutical Research, 2015; 4(6): 1191-1200.
Kaur M, Singh M. β-Carotene- β- cyclodextrin inclusion complex: Towards enhanced aqueous solubility. Journal of Global Biosciences, 2016; 5(2): 3665-3675.
Kit GO, Fung YT, et al. Enhancement of norfloxacin solubility via inclusion complexation with β-cyclodextrin and its derivative hydroxypropyl-β-cyclodextrin. Asian Journal of Pharmaceutical Sciences, 2016; 11: 536-546.
Mogal P, Derle D. Use of solid dispersions and inclusion complexation for enhancing oral bioavailability of ziprasidone in treating schizophrenia. Journal of Drug Design and Medicinal Chemistry, 2017; 3(3): 37-48.
